Ridgemont inks fourth deal since spin-out
The firm has purchased a majority stake in Gallus BioPharmaceuticals, its fourth acquisition since spinning out of Bank of America last August.
5 January 2013•1 min read
The firm has purchased a majority stake in Gallus BioPharmaceuticals, its fourth acquisition since spinning out of Bank of America last August.
